GLP-1 Drugs & Weight Loss: New Nutritional Deficiency Risks & Guidance
- Recent investigations have highlighted a potential risk of nutritional deficiencies associated with the use of GLP-1 receptor agonists, medications increasingly prescribed for both type 2 diabetes and obesity.
- GLP-1 receptor agonists, including medications like Trulicity, Victoza, Xultophy, Ozempic, Saxenda, Wegovy, and Mounjaro, work by mimicking the effects of the naturally occurring GLP-1 hormone, which regulates appetite...
- A national pharmacovigilance investigation, recently published in January, brought this risk to the forefront.
Recent investigations have highlighted a potential risk of nutritional deficiencies associated with the use of GLP-1 receptor agonists, medications increasingly prescribed for both type 2 diabetes and obesity. Healthcare providers are adapting recommendations for patients using these drugs, with a growing emphasis on dietary support and monitoring.
GLP-1 receptor agonists, including medications like Trulicity, Victoza, Xultophy, Ozempic, Saxenda, Wegovy, and Mounjaro, work by mimicking the effects of the naturally occurring GLP-1 hormone, which regulates appetite and blood sugar levels. While highly effective for weight loss and diabetes management, these medications can also lead to reduced food intake and altered eating habits, potentially increasing the risk of nutrient deficiencies.
A national pharmacovigilance investigation, recently published in January, brought this risk to the forefront. In response, professional nutritional societies and specialized obesity centers have integrated dietary management into the care pathway for adult patients with obesity. This includes recommending baseline blood tests to assess nutritional status.
Identifying and Addressing Nutritional Risks
The recommended baseline bloodwork includes a complete blood count (CBC), platelet count, electrolyte panel, iron studies (ferritin, saturation), kidney function tests (creatinine, estimated glomerular filtration rate – eGFR), C-reactive protein (CRP), albumin levels, calcium, vitamin B9 (folate), and vitamin B12. These tests help identify existing deficiencies and assess the risk of developing them.
Alongside blood tests, a clinical evaluation of eating behavior and an estimation of dietary intake are crucial. Based on these assessments, healthcare providers may prescribe protein supplementation and a multivitamin to address potential deficiencies.
New guidance emphasizes the importance of ensuring adequate caloric intake – a minimum of 1200 kcal per day – and sufficient protein consumption, aiming for more than 60 grams per day, prioritizing animal protein sources. Patients are advised to consider frequent, smaller meals and snacks, including dairy products, one to two hours after main meals. Starting meals with protein and avoiding appetizers are also recommended strategies.
Recognizing and Managing Side Effects
GLP-1 receptor agonists can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, abdominal pain, and constipation. These side effects can further complicate nutritional intake and exacerbate the risk of deficiencies. The new guidance provides recommendations for managing these side effects, including dietary adjustments.
The pharmacovigilance investigation, conducted between and , identified nutritional deficiencies as a potential safety signal requiring enhanced monitoring. Documented deficiencies included anemia, significant muscle mass loss (potentially greater than with traditional dieting), and neurological complications linked to severe vitamin B1 deficiency.
The Link Between Weight Loss and Nutritional Status
These deficiencies are thought to be caused by a combination of factors: reduced food intake, changes in the quality of food consumed, and the gastrointestinal side effects of GLP-1 receptor agonists. It’s important to remember that weight loss, while beneficial for overall health, does not automatically equate to improved nutritional status.
The increasing use of these medications, coupled with the potential for nutritional deficiencies, underscores the need for comprehensive patient support. The Australian researchers who recently warned about the potential for scurvy – historically known as the “pirate disease” due to vitamin C deficiency – highlight the importance of a balanced diet while on these medications. A recent case involving British pop singer Robbie Williams, who was diagnosed with scurvy in while taking a weight-loss medication, further illustrates this risk.
The FDA has also expressed concerns regarding unapproved compounded versions of GLP-1 drugs used for weight loss, emphasizing the importance of using medications as prescribed and discussing any concerns with a healthcare provider.
Looking Ahead
The findings from the pharmacovigilance investigation and the subsequent recommendations from medical societies emphasize a shift towards a more holistic approach to obesity and diabetes management. This approach recognizes that medication is only one component of a successful treatment plan and that nutritional support is essential for maximizing benefits and minimizing risks. Patients prescribed GLP-1 receptor agonists should discuss their dietary needs and potential risks with their healthcare provider to ensure they receive appropriate monitoring and support.
Ongoing surveillance and research are crucial to further understand the long-term effects of these medications on nutritional status and to refine recommendations for patient care. The goal is to help individuals achieve their weight loss and health goals safely and effectively, without compromising their nutritional well-being.